rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    RARE
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Ultragenyx at Jefferies Global Healthcare Conference: profit path in focus
      Nov 17Investing.comRAREJEF
      Ultragenyx Pharmaceutical Targets 2027 Profitability After Deep Cuts and Gene Therapy Launches
      Nov 17Yahoo FinanceRARE
      Ultragenyx: Gene Therapies Must Show, Not Tell, Initiating Hold (NASDAQ:RARE)

      Ultragenyx Pharmaceutical's two major late-stage pipeline failures have reset investor sentiment. Find out why RARE stock is a Hold.

      Nov 12Seeking AlphaRARE
      Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

      BASEL, Switzerland, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ultra-rare genetic diseases, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) accepted on 28th October 2026 the Company’s Marketing Authorisation Application (MAA) for rebisufligene etisparvovec (also known as rebi-vec or UX111), an investigational gene therapy for the tre

      Nov 6Yahoo FinanceRARE
      Ultragenyx Pharmaceutical Inc (RARE) Q3 2026 Earnings Call Highlights: Gene Therapy Launches, ...
      Nov 5Yahoo FinanceRARE
      Ultragenyx: Still Lacking Appeal Despite 'Commercial-First' Pivot (NASDAQ:RARE)

      Ultragenyx remains a cautious Hold as R&D cuts support profitability, while CRYSVITA concentration and pipeline setbacks cloud growth. Learn more about RARE stock here.

      Nov 4Seeking AlphaRARE
      Ultragenyx Pharmaceutical (RARE) Stock Looks Fairly Valued After Upcoming FDA Decisions

      Ultragenyx Pharmaceutical has seen its stock lose ground over several years even as new rare disease treatments and regulatory decisions continue to reshape its outlook. With the share price recently around US$16.63 after a long slide, the live question is whether what investors are paying today lines up with the company’s current level of sales. Over the past 5 years, Ultragenyx Pharmaceutical shares have fallen 79.4%, which puts a sharper focus on whether the remaining valuation is still...

      Nov 4Yahoo FinanceRARE
      Ultragenyx Pushes Toward Profitability in 2027, Led by Pruned Pipeline, Layoffs
      Nov 4BenzingaRARE
      Gene Therapy Launches Could Be A Game Changer For Ultragenyx Stock (RARE)
      Nov 4Yahoo FinanceRARE
      Wells Fargo raises Ultragenyx Pharma price target to $19 on costs
      Nov 4Investing.comRARE
      Ultragenyx Pharmaceutical (RARE) Recasts The Story After FDA Approvals As Valuation Debate Builds

      Ultragenyx Pharmaceutical (RARE) is in focus after receiving FDA approvals for its first two commercial gene therapies, GENGLYCOS and FAYUVI, while simultaneously cutting 20% of its workforce and discontinuing two development programs. The latest moves have arrived after a volatile stretch for Ultragenyx Pharmaceutical, with a 1-month share price return of 9.26%. However, a 90-day share price decline of 33.29% and a 1-year total shareholder return decline of 48.77% point to longer term...

      Nov 4Yahoo FinanceRARE
      What Ultragenyx Pharmaceutical (RARE) Said on Its Q3 Earnings Call
      Nov 4Yahoo FinanceRARE
      Earnings call transcript: Ultragenyx misses Q3 2026 estimates as stock falls after hours
      Nov 3Investing.comRARE
      Ultragenyx Pharmaceutical Q3 2026 Earnings Call Transcript
      Nov 3BenzingaRARE
      Ultragenyx earnings missed by $0.06, revenue fell short of estimates
      Nov 3Investing.comRARE
      Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates
      Nov 3Yahoo FinanceRARE
      Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics

      While the top- and bottom-line numbers for Ultragenyx (RARE) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

      Nov 3Yahoo FinanceRARE
      Ultragenyx: Q3 Earnings Snapshot
      Nov 3Yahoo FinanceRARE
      Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027
      Nov 3Yahoo FinanceRARE
      Ultragenyx in focus as earnings test commercial execution
      Nov 3Investing.comRARE
      How one family gave a critical boost to gene therapy research

      A family affected by Sanfilippo syndrome raised millions of dollars for research. The Food and Drug Administration just approved a gene therapy the support helped make possible.

      Nov 1NPRJBSSRARE
      Ultragenyx (RARE) vs. SRPT and BMRN: Can Upcoming Drug Approvals Unlock the Next Phase of Biotech Growth?
      Oct 30Yahoo FinanceRARE
      FDA draft guidance aims to speed personalized gene therapies for rare diseases (RARE:NASDAQ)
      Oct 29Seeking AlphaRARE
      Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
      Oct 27Yahoo FinanceJAZZRARE
      A family's fundraising for gene therapy research pays off

      After their daughter was diagnosed with a rare inherited disease in 2013, the O'Neill family raised money to find a treatment. The Food and Drug Administration recently approved a gene therapy.

      Oct 22NPRRARE
      Ultragenyx CFO Howard Horn sells $107,897 in company stock
      Oct 19Investing.comRARE
      Ultragenyx Pharmaceutical Enters Settlement With Navinta Over Dojolvi
      Oct 19Yahoo FinanceRARE
      RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week

      Ultragenyx agrees to sell its Fayuvi-linked PRV for $203 million, marking its second voucher sale in one week and adding non-dilutive funding for rare-disease programs.

      Oct 15Yahoo FinanceRARE
      Ultragenyx to sell Fayuvi FDA priority review voucher for $203M
      Oct 14Seeking AlphaRARE
      Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?
      Oct 14Yahoo FinanceRARE
      Ultragenyx to sell priority review voucher for $203 million
      Oct 14Investing.comRARE
      Analysts Conflicted on These Healthcare Names: Quantum-Si (QSI), Crispr Therapeutics AG (CRSP) and Ultragenyx Pharmaceutical (RARE)

      Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailCRSPQSIRARE
      Analysts Have Conflicting Sentiments on These Healthcare Companies: Verastem (VSTM), Ultragenyx Pharmaceutical (RARE) and UnitedHealth (UNH)

      Detailed price information for Unitedhealth Group (UNH-N) from The Globe and Mail including charting and trades.

      Oct 9The Globe and MailRAREVSTM
      Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash

      RARE enters into an agreement to sell a Rare Pediatric Disease PRV for $210M, adding non-dilutive cash as it advances rare-disease therapies.

      Oct 8Yahoo FinanceRARE
      H.C. Wainwright reiterates Ultragenyx stock rating on PRV sale
      Oct 8Investing.comRARE
      Is Ultragenyx Pharmaceutical (RARE) Undervalued Following EMA Validation For Its Sanfilippo Gene Therapy?
      Oct 8Yahoo FinanceJBSSRARE
      Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million
      Oct 7Yahoo FinanceRARE
      Ultragenyx Lands $210M Deal To Sell FDA Priority Review Voucher – Retail Sees ‘Huge’ Buying Opportunity
      Oct 7Yahoo FinanceRARE
      Ultragenyx to sell FDA priority review voucher for $210M (RARE)

      Ultragenyx Pharmaceutical (RARE) stock gains as the company inks a $210M deal to sell an FDA priority review voucher tied to recent Genglycos approval. Read more here.

      Oct 7Seeking AlphaRARE
      Ultragenyx to sell rare disease priority review voucher for $210m
      Oct 7Investing.comRARE
      Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
      Oct 7Yahoo FinanceRARE
      Ultragenyx (RARE) EMA Validation of MPS IIIA Gene Therapy: Inflection Point or Incremental Milestone?
      Oct 7Yahoo FinanceRARE
      Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation

      RARE's gene therapy for Sanfilippo syndrome wins EMA validation, advancing the treatment toward formal review in Europe.

      Oct 5Yahoo FinanceJBSSRARE
      H.C. Wainwright reiterates Ultragenyx stock rating on FDA approval
      Sep 25Investing.comRARE
      RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results

      Ultragenyx shares are trading around $16 after gaining about 9% this week, rebounding from the $12.73 low hit earlier this month.

      Sep 22Yahoo FinanceRARE
      FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target?
      Sep 22Yahoo FinanceRARE
      Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP), Ultragenyx Pharmaceutical (RARE) and Novavax (NVAX)

      Tipranks Press Release.

      Sep 22The Globe and MailNVAXRARE
      Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE)

      Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.

      Sep 22The Globe and MailRAREMRKNVST
      Weekly Note: Ultragenyx (RARE): FAYUVI Full Approval Clears The Binary: Upgrade To Buy, Execute Stage Two
      Sep 21Seeking AlphaRARE
      How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVI

      In September 2026, Ultragenyx Pharmaceutical received full U.S. FDA approval for FAYUVI (UX111), the first-ever treatment for pediatric patients with Sanfilippo syndrome Type A, along with a Priority Review Voucher. This approval not only addresses a previously untreated ultra-rare, fatal neurodegenerative disease but also expands Ultragenyx’s commercial gene therapy portfolio and manufacturing footprint in the U.S. We’ll now explore how FAYUVI’s first-in-disease approval and the associated...

      Sep 19Yahoo FinanceRARE

      This is the newest page. Registered accounts read further back.